The FDA has approved Kerendia® (finerenone) to reduce the risk of cardiovascular death, hospitalization for HF, and urgent HF visits.

Patients with heart failure and atrial fibrillation (AF) at the time of mitral transcatheter edge-to-edge repair (M-TEER) for ...

BACKGROUND: Neurodevelopmental and functional impairments are among the most consequential morbidities for survivors of ...

The study revealed that people with these genetic changes were found to be more than twice as likely to develop heart failure ...

Researchers at the German Center for Cardiovascular Research (DZHK) have identified a key molecule involved in a form of ...

Patients with heart failure and atrial fibrillation (AF) at the time of mitral transcatheter edge-to-edge repair (M-TEER) for ...

Bayer announced the FDA approved finerenone, a nonsteroidal selective mineralocorticoid receptor antagonist, for the ...

Background Although treatment options for heart failure (HF) have improved, advanced HF (AdHF) remains a challenging ...

SGLT2 inhibitors reduced heart failure events and cardiovascular death in patients with heart failure, type 2 diabetes, chronic kidney disease, and atherosclerotic cardiovascular disease. These ...

Patients with type 2 diabetes mellitus are at a higher risk of developing heart failure compared with the healthy population. In recent landmark clinical trials, sodium-glucose co-transporter 2 (SGLT2 ...

A rare heart risk warning must now come on COVID vaccines despite CDC's previous findings The CDC previously concluded there was no increased risk of myocarditis detected in government vaccine ...

U.S. health officials have expanded warnings about a rare heart side effect associated with the two leading COVID-19 vaccines.